Glenmark gets FDA nod for chlorzoxazone

Press enter to search
Close search
Open Menu

Glenmark gets FDA nod for chlorzoxazone

By Sandra Levy - 05/29/2020

Patients with muscle spasms and pain will soon have a new generic treatment option.

The Food and Drug Administration has cleared Glenmark’s chlorzoxazone tablets in dosage strengths of 375 mg and 750 mg.

This marks Glenmark’s first abbreviated new drug application approval from their new North American manufacturing facility based in Monroe, N.C.

The product has a market value of roughly $20.9 million, for the 12 months ended March 2020, according to IQVIA.


Related Topics